

Anakinra in Sanfilippo syndrome: a phase 1/2 trial

Received: 6 December 2023

Accepted: 19 May 2024

Published online: 21 June 2024



Lynda E. Polgreen^{1,2}✉, Agnes H. Chen^{1,2}, Youngju Pak^{1,2}, Anna Luzzi¹, Adolfo Morales Garval¹, Jonathan Acevedo¹, Gal Bitan^{1,3}, Michelina Iacovino^{1,2}, Cara O'Neill⁴ & Julie B. Eisengart^{1,5}

Sanfilippo syndrome is a fatal childhood neurodegenerative disorder involving neuroinflammation among multiple pathologies. We hypothesized that anakinra, a recombinant interleukin-1 receptor antagonist, could improve neurobehavioral and functional symptoms owing to its capacity to treat neuroinflammation. This phase 1/2 trial aimed to test the safety, tolerability and effects of anakinra on neurobehavioral, functional and quality-of-life outcomes in patients and their caregivers. The primary outcome was the percent of participants requiring a dose increase at week 8 or week 16. Secondary efficacy outcomes included a multi-domain responder index (MDRI). Twenty-three participants (6–26 years of age) were enrolled. Twenty continued treatment to week 8, and 15 (75%) required an increased dose at week 8 or week 16. There was an improvement in at least one domain in the MDRI in 18 of 21 (86%) at week 8 and in 15 of 16 (94%) at week 36. Seven participants withdrew (intolerability of daily injections and lost to follow-up) before week 36. Adverse events occurred in 22 of 23 (96%) participants, most commonly mild injection site reactions. No serious adverse events were related to anakinra. In conclusion, anakinra was safe and associated with improved neurobehavioral and functional outcomes, supporting continued investigation of anakinra in Sanfilippo syndrome and other mucopolysaccharidoses. ClinicalTrials.gov identifier: [NCT04018755](https://clinicaltrials.gov/ct2/show/study/NCT04018755).

Sanfilippo syndrome is a fatal childhood neurodegenerative disorder characterized by regression in development, loss of speech, disordered sleep and movement, pain and intensifying neurobehavioral symptoms, such as hyperactivity, agitation, destructiveness, distress/screaming and social disengagement. Symptom onset often begins around age 3–5 years, followed by an unremitting disease course culminating in death in the second or third decade of life^{1–4}.

There are no approved therapies for Sanfilippo syndrome. Scientifically referred to as mucopolysaccharidosis type III (MPS III), it

is one of a group of seven mucopolysaccharidosis disorders defined by deficiency in lysosomal enzymes critical to degrading glycosaminoglycans (GAGs)⁵. Accumulating GAGs trigger pathological cascades and cellular dysfunction that lead to worsening clinical disease⁶. Enzyme-restorative approaches have been successful in attenuating or halting disease progression in most other forms of MPS⁷, but none has been approved for any of the MPS III subtypes⁸.

As the pursuit of enzyme restoration continues, there is urgency to palliate symptoms that cause suffering for most of the Sanfilippo

¹Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. ²Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. ³Department of Neurology, David Geffen School of Medicine, Brain Research Institute and Molecular Biology Institute University of California, Los Angeles, Los Angeles, CA, USA. ⁴Cure Sanfilippo Foundation, Columbia, SC, USA. ⁵Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. ✉e-mail: lpolgreen@lundquist.org




Fig. 1 | CONSORT flowchart. Anakinra treatment for the 8-week open label from day 1 to week 8 with 28-week open-label extension. Treatment occurred from day 1 to week 36. Observation occurred for 8 weeks before day 1 and for another 8 weeks starting at week 36 when treatment was stopped. The primary enrollment target was 20 on treatment at week 8. $n = 3$ patients stopped

treatment but continued the study by completing assessments through week 44: one before week 8 (stopped treatment owing to a grade 3 AE of increased agitation) and two between week 8 and week 36 (stopped treatment owing to persistent ANC < 1,500 cells per microliter).

community. Although clinical endpoints of most MPS III clinical trial programs have focused on neurocognitive decline, recent publications have indicated that pain, disordered sleep and movement and neurobehavioral symptoms are among the most important symptoms to the Sanfilippo community to treat^{9,10}. Fortunately, community voicing of these therapeutic needs has been strengthened by a substantial increase in regulatory, scientific and clinical emphasis on these treatment outcomes that are meaningful to patients and families^{11,12}.

An expansion of therapeutic approach is needed to treat these symptoms by targeting the pathological cascades triggered by GAG buildup, including neuroinflammation^{13–21}, which likely underlies many of the challenging neurobehavioral and functional signs of the disease. Results have been encouraging in MPS III murine models, as central nervous system (CNS) disease and behavior are improved when inflammation is successfully decreased, such as by increasing interleukin-1 receptor antagonist (IL-1Ra) via hematopoietic stem cell gene therapy or knocking out the IL-1 receptor^{13,14,16,18,19}.

A critical opportunity to apply this alternative approach in humans is afforded by repurposing anakinra (Kineret, Swedish Orphan Biovitrum AB), a recombinant human IL-1Ra that treats other neuroinflammatory diseases^{22–26}. Anakinra is approved by the US Food & Drug Administration (FDA) for treatment of cryopyrin-associated periodic syndromes (CAPS), neonatal-onset multi-inflammatory disease (NOMID), deficiency of interleukin-1 receptor antagonist (DIRA) and rheumatoid arthritis. We hypothesized that anakinra could improve neurobehavioral and functional symptoms owing to its capacity to treat both central and peripheral inflammation triggered by GAG accumulation. Here we present the final report on a phase 1/2 study of anakinra in Sanfilippo syndrome, which tested the safety, tolerability and effects on neurobehavioral, functional and quality-of-life outcomes in patients and their caregivers.

Results

Patient disposition

This was a phase 1/2, 8-week open-label study, followed by a 28-week open-label extension, all of which were preceded and followed by 8-week observational periods (NCT04018755; see protocol in the Supplementary Information). Twenty-four participants (12 males and 12 females) aged 6–26 years were screened, and 23 were enrolled (Fig. 1). One participant was excluded owing to persistent neutropenia during the screening process. Once enrollment was complete, potential participants more than doubling the study size ($n = 27$) chose to join a waitlist in the event the study was expanded or extended or future trials were to be developed. Baseline characteristics of enrolled participants are shown in Table 1. Most participants were categorized by their parents/caregivers as White (88%) and not Hispanic (88%). Although speaking English was not an inclusion criterion, all caregivers who completed surveys spoke and read English fluently.

Five participants withdrew owing to intolerability of daily subcutaneous (SC) injections (two before week 8 and three between weeks 16 and 36); two participants were lost to follow-up; and three participants were withdrawn by the principal investigator owing to adverse events (AEs), one for a grade 3 AE and two for persistent neutropenia (<1,500 cells per microliter), withdrawn before the decision to lower the study neutropenia threshold to 1,200 cells per microliter. Reasons for intolerability were reported as difficulty keeping the participant still for injections, particularly when only one caregiver was routinely available; participant distress in anticipation or delivery of injections; and overall burden of route of administration.

Primary outcome(s)

Dosing. Anakinra was started on day 1 at an SC daily dose of 100 mg. Dose escalations were made as follows. Either at week 8 or at week 16 (if not changed at week 8), the daily dose of anakinra was increased to

Table 1 | Patient characteristics at baseline (n=24)

Age (years)	
Mean±s.d.	10.6 ± 4.2
Median	9.7
Range	6.3–26.1
Race – no. (%) ^a	
White	21 (88)
Black	1 (4)
Asian	1 (4)
Other	1 (4)
Ethnicity – no. (%) ^a	
Hispanic	3 (13)
Non-Hispanic	21 (88)
Sex – no. (%)	
Female	12 (50)
Male	12 (50)
MPS type – no. (%)	
MPS IIIA	20 (83)
MPS IIIB	3 (13)
MPS IIIC	1 (4)
Past experimental therapy – no. (%) ^b	
Gene therapy	3 (13)
Enzyme replacement therapy	3 (13)
Vineland Adaptive Behavior Scales ⁴¹ , Third Edition, Adaptive Behavior Composite ^c	
Mean±s.d.	42
Median	37
Range	25–69

^a Race and ethnic group were reported by the participant's parent/caregiver. ^b Participants were not currently enrolled in another ongoing therapeutic clinical trial. ^c Normative population mean±s.d. is 100±15. Scores within one standard deviation of the mean—that is, 85–115—are in the 'average' range, whereas 70–84 is below average, and less than 70 is impaired³⁴.

200 mg SC daily if there was not an improvement from day 1 to week 8 (or week 16) of more than the predefined minimal clinically important difference^{27,28} (MCID—that is, the smallest improvement considered worthwhile to a patient) in the two outcomes chosen by the parent/caregiver to be 'most bothersome' at screening. Of the 20 participants who continued treatment to week 8, 12 (60%) required an increased dose of anakinra from 100 mg SC daily to 200 mg SC daily at week 8, owing to lack of improvement; three additional participants had their dose increased at week 16. No statistically significant differences were observed between those who dose escalated and those who did not in age, sex, race or ethnicity, nor in efficacy assessments at baseline.

Safety. Mean treatment duration was 187 ± 92 d, and doses missed were, on average, 5.2 ± 6.6 doses. Table 2 summarizes AEs that occurred in at least 5% of participants during treatment with anakinra, and Extended Data Table 1 summarizes all AEs occurring during the overall study. Of the 23 participants who received at least one dose of anakinra, 22 (96%) reported at least one AE during the study; the most common AEs were injection site reactions, most frequently erythema and swelling, reported in 74% and 43%, respectively. There were no unexpected AEs. Three serious adverse events (SAEs) occurred, none of which was determined to be related to anakinra exposure: two during treatment with anakinra (viral pneumonia and injury (muscle laceration)) and one after treatment (upper gastrointestinal hemorrhage).

Table 2 | AEs that occurred in at least 5% of participants

AE	On treatment (n=23)				After treatment ^a (n=16)			
	Incidence		Event rate		Incidence		Event rate	
	n	%	n	Rate	n	%	n	Rate
Participant with any SAE ^b	2	9%	2	0.09	1	4%	1	0.04
Participant with any AE	22	96%	408	17.74	15	65%	52	2.26
Injection site AEs								
Injection site reaction (any)	18	78%	326	14.17				
Injection site erythema	17	74%	165	7.17				
Injection site swelling	10	43%	52	2.26				
Injection site bruising	5	22%	41	1.78				
Injection site itching	3	13%	65	2.83				
Injection site bleeding	3	13%	3	0.13				
Non-injection site AEs								
Upper respiratory infection	7	30%	8	0.35	4	17%	4	0.17
Constipation	4	17%	5	0.22	4	17%	4	0.17
Agitation	4	17%	4	0.17	2	9%	2	0.09
Neutropenia	6	26%	9	0.39	1	4%	1	0.04
COVID-19—mild symptoms	5	22%	5	0.22	0	0%	0	0.00
Diarrhea	4	17%	4	0.17	1	4%	1	0.04
Acute otitis media	2	9%	2	0.09	2	9%	3	0.13
Thrombocytopenia	4	17%	4	0.17	1	4%	1	0.04
Rash	1	4%	1	0.04	2	9%	2	0.09
Seizures	1	4%	1	0.04	2	9%	3	0.13
Stiffness in arms and legs	1	4%	1	0.04	2	9%	2	0.09
Bronchitis	2	9%	2	0.09	0	0%	0	0.00

^a AEs occurring either after early drug discontinuation for participants who continued in the study off treatment or after discontinuation of treatment at week 36 to week 48. Complete reporting of AEs is available in Extended Data Table 1 ^b No treatment-related SAEs.

Secondary outcomes

Secondary outcomes, to evaluate efficacy, were selected to account for the heterogeneity of MPS III symptoms, informed by the caregiver community^{9,10} and consensus recommendations on Sanfilippo trial design^{29,30}. A multi-domain responder index (MDRI) and an individual clinical response (ICR) were used to capture heterogeneity in treatment response, similar to what was used previously^{31,32}. Most participants showed improvement beginning at 8 weeks of treatment as demonstrated by the MDRI approach for measuring heterogeneous treatment effects (Fig. 2). Specifically, 18 of 21 (86%) participants improved on one or more of the six outcomes included in the MDRI at week 8, and 15 of 16 (94%) participants improved on one or more of the six outcomes at week 36. After 8 weeks of treatment, improvement of more than the MCID was most common for parenting stress (48%), measured by the Autism Parenting Stress Index (APSI), and pain (48%), measured by the Non-Communicating Children's Pain Checklist—Revised (NCCPC-R). After 36 weeks of treatment, improvement was still most common for parenting stress (69%), but the second-most common improvement was




Fig. 2 | MDRI: comparison of change during 8 weeks (a), 16 weeks (b) and 36 weeks (c) of treatment to MCID. A change during treatment with anakinra relative to the MCID was used to define 'improved', 'no change' and 'worsened'. MCID definitions can be found in Methods, 'Secondary outcomes'.




Fig. 3 | Change in the SBRS individual clusters and domains before, during and after treatment with anakinra. The treatment period was from week 0 to week 36. The black line graph with circle symbols shows the observed least-squares means with 95% CIs for patients with available data (observed) over time. The imputed least-squares means for the pre-specified sensitivity analysis are plotted as gray lines with square symbols. *P* values are for change in observed least-squares means from day 1. A return of symptoms after 8 weeks

off treatment, seen by the upward slope to week 44, suggests that the reduction of symptoms from week 0 to week 36 was not part of the natural disease course. There was no statistically significant difference in SBRS scores between week 44 and day 1. All statistical tests were two-sided, including the Wald test with 23 degrees of freedom from the mixed model. No adjustment was made for multiple comparisons. LS mean, least-squares mean.

behavioral symptoms (56%), measured by the total averaged score on the Sanfilippo Behavior Rating Score (SBRS), followed by pain (44%).

Based on the estimated least-squares means, there was an improvement in the ICR from day 1 to week 8 (−2.0, 95% confidence interval (CI): −3.4, −0.6), from day 1 to week 16 (−2.8, 95% CI: −4.9, −0.8) and from day 1 to week 36 (−2.7, 95% CI: −4.3, −1.0). A return of symptoms after 8 weeks without treatment is demonstrated in the upward slope (that is, increased severity) between week 36 and week 44 (Extended Data Fig. 1). There was no difference in ICR between the last day of the pre-dosing observational period and the last day of the post-dosing observational period (0.93, 95% CI: −1.18, 3.04).

Estimated least-squares means and 95% CIs before, during and after treatment with anakinra in the SBRS clusters (Movements, Social/Emotional Dysfunction, Lack of Fear and Executive Dysfunction) and

domains (Orality and Mood/Anger/Aggression) are shown in Fig. 3 and Extended Data Table 2, and descriptive statistics are shown in Extended Data Table 3. There was a positive effect of treatment in all clusters and domains of the SBRS except for the Lack of Fear and Executive Dysfunction clusters, where there was no statistically significant response to treatment with anakinra. On all clusters and domains except for the Lack of Fear cluster, a return of symptoms off treatment is depicted in the upward slope between week 36 and week 44, indicating rebounding frequency of symptoms (Fig. 3). There was no difference in any of the SBRS clusters or domains between the last day of the pre-dosing observational period and the last day of the post-dosing observational period (Extended Data Table 2).

The least-squares mean difference in parenting stress measured by the APSI from day 1 to week 16 was −2.9 (95% CI: −5.2, −0.7) and from




Fig. 4 | Immunophenotype changes compared to the MDRI. a, Flow cytometry plot of whole blood stained with specific antibodies to identify monocytes. Whole blood cells were gated on live cells and then sub-gated on CD19⁺ cells (to exclude B cells), CD3⁺ cells (to exclude T cells) and CD56 cells (to exclude NK cells). Cells that were not bright CD16 (neutrophils) in the side scatter plot (SSC) plot were identified as monocytes. These cells expressed CD14 and CD16. **b,** B lymphocytes were identified as CD19⁺ cells and CD3⁺ cells. T lymphocytes CD4 and CD8 were sub-gated from CD3⁺ cells. **c,** Trends for changes in CD4⁺ T cells (for example, T helper and T regulatory cells), CD8⁺ T cells (for example, cytotoxic T cells), monocytes and B cells over 16 weeks of treatment with anakinra, compared to the MDRI. The number of MDRI surveys with a treatment response that was either improved (black triangles/solid line) or worsened

(open circles/dashed line), as defined by the MCID, is plotted with immunophenotype data as percent of the cell population. The y-axis is absolute change in percent of the cell population. Positive numbers are an increase in cell population, and negative numbers are a decrease in cell population. An increase in CD4⁺ T cells with a decrease in CD8⁺ T cells and a decrease in monocytes is suggestive of a less pro-inflammatory environment. This less pro-inflammatory environment is the desired change with therapy. These changes coincide with a higher number of improvements on the MDRI outcomes. Anakinra is not expected to have a significant effect on B cells. The lack of B cell change and lack of relationship with MDRI outcomes may increase confidence in the findings. *Spearman's rank-based correlation coefficient $P < 0.05$. SSC-A, side scatter area.

day 1 to week 36 was -3.8 (95% CI: $-6.8, -0.8$). No significant changes were observed in least-squares means for the Child Sleep Health Questionnaire (CSHQ), the PROMIS Fatigue–Parent Proxy Custom Short Form, the disordered movement 7-d log or the NCCPC-R. Least-squares means for all the MDRI outcomes are detailed in Extended Data Table 4, and descriptive statistics are provided in Extended Data Table 5.

Post hoc analyses

Post hoc analysis to investigate a relationship of the biochemical effects of anakinra with the clinical effects found a statistically significant correlation between an increase in CD4⁺ T cells and a higher number of improved outcomes in the MDRI (Fig. 4). Although correlations with other cell types in this small sample did not reach statistical significance, in general, the less pro-inflammatory the environment (the desired effect—that is, an increase in CD4⁺ T cells and decreases in CD8⁺ T cells and in monocytes), the more the MDRI outcomes showed improvements (Fig. 4). In contrast, MDRI outcomes that showed worsening were associated with more pro-inflammatory markers—that is, decrease in CD4⁺ T cells and increases in CD8⁺ T cells and in monocytes.

Discussion

Curative therapies for Sanfilippo syndrome are in development, but the lack of any approved disease-modifying treatment creates urgency to palliate the challenging symptoms of this largest affected segment of the MPS population. Discovery of the key pathologic role of neuroinflammation in MPS has led to critical opportunities to examine the potential for attainable relief on a shorter timeline by reducing inflammation and its clinical correlates¹³. This study of anakinra in Sanfilippo syndrome is, to our knowledge, the first in-human study to repurpose an FDA-approved, blood-brain-barrier-crossing, anti-inflammatory therapy to target CNS inflammation in MPS. Aligned with the purpose of a phase 1/2 trial, our findings indicate that anakinra is safe for further investigation while curative therapies are in development. Furthermore, findings show clinically meaningful improvements in various neurobehavioral and quality-of-life outcomes, suggesting that an anti-inflammatory approach might prove to be symptom modifying for Sanfilippo syndrome.

No new safety concerns were identified. All AEs were mild or moderate, and no SAEs were considered to be related to anakinra.

However, a high number of participants withdrew, primarily owing to the challenge of administering daily SC injections. Specifically, two caregivers were often needed to hold the participant and administer the injection, due to the highly physical and dysregulated behaviors of Sanfilippo syndrome. In single-caregiver households, the challenge of daily injections was considerable.

The design of this trial and the choice of endpoints were founded on consensus guidelines for MPS III (ref. 29), patient/caregiver input^{9,10} and FDA guidance to include patient and community input when designing trials^{12,33}. Unlike enzyme-restorative trials for MPS III, this study differed in a few key ways: (1) inclusion of patients with advanced disease and across all MPS III disease subtypes; (2) incorporation of the Sanfilippo community perspective in the design and execution of the trial; and (3) use of a composite measure to capture heterogeneous treatment effects. The composite measure in this trial was an MDRI, an approach that evaluates a broad, heterogeneous array of clinical disease manifestations to understand fully the treatment effects³². The MCID enables interpretation of the meaningfulness of individual numeric changes on a variety of outcome measures. The patient perspective was incorporated at study conception, trial design and through study completion via partnership with the one of the largest Sanfilippo syndrome patient advocacy groups, which has a global reach, and further involvement of its chief science officer as a co-investigator. This close partnership allowed the study team deeper insights into the community's priorities. Recognizing the need to capture the effect of treatment upon individuals' most meaningful symptom targets, and that those targets may vary in importance from patient to patient, we developed an individual clinical response measure. This newly developed measure allowed caregivers to choose outcomes that mattered the most to them, and, thus, we could collect more personalized data on longitudinal treatment impacts with inherent meaningfulness.

The severity of disease in our cohort was by design to ensure improved representation of the substantial segment of the Sanfilippo community who have been excluded from enzyme-restorative trials. It further ensured that this study would not compete with potentially curative trials that target neurocognitive decline. Targeting neurocognition is not feasible in our study population as this aspect of function is often very low and minimally changing past the age of 6 years in most MPS III types^{34–36}. Although the historical focus on neurocognition has been key to revealing whether enzyme-restorative trials modify the course of decline^{34,36}, this focus does not address many of the symptoms prioritized by the patient community^{9,10}, which was the emphasis of the present study.

The SBRS was included because it has been validated in Sanfilippo samples³⁷, correlated with biomarkers^{37–39} and recommended for trial use at two international meetings^{29,30}. The SBRS identified a positive effect of anakinra in all clusters and domains, except for the Lack of Fear cluster, which was anticipated, and Executive Dysfunction. Given Sanfilippo-related atrophy of the amygdala^{37–39}, a subcortical structure linked to fear, we did not expect decreasing inflammation to have a substantial effect on the SBRS Fear cluster. These non-findings in the Lack of Fear domain may strengthen the validity of this study's positive SBRS findings on the other domains and clusters.

The natural histories of this study's endpoints have not been reported as plentifully as neurocognition or adaptive behavior in Sanfilippo syndrome. Therefore, we examined these endpoints in untreated individuals during the observational periods, balancing the duration of observation with the urgency to relieve symptoms. An important consideration was the natural reduction in symptoms associated with neurodegeneration: neurobehavioral manifestations lessen as the disease progresses⁴⁰, due to continual loss in multiple functions coincident with neurodegeneration. Thus, we remained mindful that the appearance of improvement in symptom intensity can be a sign of progressing disease, which we did not want to mistake for therapeutic

benefit. After cessation of anakinra, target symptoms rebounded to pre-dosing severity/frequency, suggesting that the reduction in symptoms during the treatment period was not explained by disease progression. Across domains, upward trajectories of symptoms (that is, worsening) when the patients come off treatment to the end of untreated observation increase optimism that the period of improvement is related to anakinra.

This study has several limitations. Although it is common that a placebo is not part of a phase 1/2 study, our decision not to include placebo in this early investigation was also an ethical one, as anakinra is given as a daily SC injection. This does, however, mean that our results need to be interpreted with caution. For example, the ICR has clinical importance because it was developed to prioritize caregiver concerns, but it is prone to effect size inflation, especially in this non-controlled study. We also recognize that interpretation of efficacy is limited by caregiver report in an unblinded trial. However, it was the only feasible method to assess the community-specified target symptoms^{9,10} because affected children in this study's age range typically have severely impaired communication and cognition. Furthermore, post hoc analysis did show a correlation of a less inflammatory immunophenotype aligning with caregiver report of benefits. As a final point, although efforts were made to use assessment tools that addressed the priority symptoms of Sanfilippo syndrome, even these methods could not fully capture all types of benefits described by caregivers via investigator patient history interviews, spontaneous reporting throughout the trial or informal exit interviews. Planned qualitative family interviews were highlighted as an important need in the design of a future trial.

The results from this phase 1/2 study provide initial evidence that targeting inflammation through the use of anakinra is safe and may improve neurobehavioral symptoms and meaningful aspects of the lived experience of patients and families affected by Sanfilippo syndrome. Findings may have broader implications for targeting central and peripheral inflammation in other MPS types as well as other neurodegenerative diseases.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-024-03079-3>.

References

- Whitley, C. B. et al. Observational prospective natural history of patients with Sanfilippo syndrome type B. *J. Pediatr.* **197**, 198–206 (2018).
- Shapiro, E. G. et al. A prospective natural history study of mucopolysaccharidosis type IIIA. *J. Pediatr.* **170**, 278–287 (2016).
- Buhrman, D., Thakkar, K., Poe, M. & Escolar, M. L. Natural history of Sanfilippo syndrome type A. *J. Inher. Metab. Dis.* **37**, 431–437 (2014).
- Héron, B. et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. *Am. J. Med. Genet. A.* **155A**, 58–68 (2011).
- Neufeld, E. & Muenzer, J. The mucopolysaccharidoses. In *The Metabolic and Molecular Basis of Inherited Disease* (eds Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D.) 3421–3452 (McGraw-Hill, 2001).
- Leal, A. F. et al. Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets. *Int. J. Mol. Sci.* **24**, 477 (2022).
- Penon-Portmann, M., Blair, D. R. & Harmatz, P. Current and new therapies for mucopolysaccharidoses. *Pediatr. Neonatol.* **64**, S10–S17 (2023).

8. Pearce, Y. & Iacovino, M. A cure for Sanfilippo syndrome? A summary of current therapeutic approaches and their promise. *Med. Res. Arch.* **8**, <https://doi.org/10.18103/mra.v8i2.2045> (2020).
9. Porter, K. A. et al. Parent experiences of Sanfilippo syndrome impact and unmet treatment needs: a qualitative assessment. *Neurol. Ther.* **10**, 197–212 (2021).
10. Porter, K. A. et al. Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome. *J. Patient Rep. Outcomes* **6**, 40 (2022).
11. Shapiro, E. et al. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. *Mol. Genet. Metab.* **118**, 65–69 (2016).
12. U.S. Food & Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. <https://www.fda.gov/media/139088/download> (2020).
13. Parker, H. et al. Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA. *EMBO Mol. Med.* **12**, e11185 (2020).
14. Mandolfo, O., Parker, H. & Bigger, B. Innate immunity in mucopolysaccharide diseases. *Int. J. Mol. Sci.* **23**, <https://doi.org/10.3390/ijms23041999> (2022).
15. Bigger, B. W., Begley, D. J., Virgintino, D. & Pshezhetsky, A. V. Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders. *Mol. Genet. Metab.* **125**, 322–331 (2018).
16. DiRosario, J. et al. Innate and adaptive immune activation in the brain of MPS IIIB mouse model. *J. Neurosci. Res.* **87**, 978–990 (2009).
17. Killedar, S. et al. Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. *J. Neuroinflammation* **7**, 39 (2010).
18. Parker, H. & Bigger, B. W. The role of innate immunity in mucopolysaccharide diseases. *J. Neurochem.* **148**, 639–651 (2019).
19. Holley, R. J. et al. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. *Brain J. Neurol.* **141**, 99–116 (2018).
20. Martins, C. et al. Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. *Brain J. Neurol.* **138**, 336–355 (2015).
21. Simonaro, C. M. et al. Involvement of the Toll-like receptor 4 pathway and use of TNF- α antagonists for treatment of the mucopolysaccharidoses. *Proc. Natl Acad. Sci. USA* **107**, 222–227 (2010).
22. Cvetkovic, R. S. & Keating, G. Anakinra. *BioDrugs* **16**, 303–311 (2002).
23. Kenney-Jung, D. L. et al. Febrile infection-related epilepsy syndrome treated with anakinra. *Ann. Neurol.* **80**, 939–945 (2016).
24. Koné-Paut, I. & Galeotti, C. Anakinra for cryopyrin-associated periodic syndrome. *Expert Rev. Clin. Immunol.* **10**, 7–18 (2014).
25. Kullenberg, T., Löfqvist, M., Leinonen, M., Goldbach-Mansky, R. & Olivecrona, H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. *Rheumatology (Oxford)* **55**, 1499–1506 (2016).
26. Cavalli, G. & Dinarello, C. A. Anakinra therapy for non-cancer inflammatory diseases. *Front. Pharmacol.* **9**, 1157 (2018).
27. Jaeschke, R., Singer, J. & Guyatt, G. H. Measurement of health status. Ascertaining the minimal clinically important difference. *Control. Clin. Trials* **10**, 407–415 (1989).
28. Chatham, C. H. et al. Adaptive behavior in autism: minimal clinically important differences on the Vineland-II. *Autism Res.* **11**, 270–283 (2018).
29. Ghosh, A. et al. Recommendations on clinical trial design for treatment of mucopolysaccharidosis type III. *Orphanet J. Rare Dis.* **12**, 117 (2017).
30. van der Lee, J. H. et al. Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints. *Mol. Genet. Metab.* **131**, 181–196 (2020).
31. Wang, R. Y. et al. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. *Mol. Genet. Metab.* **129**, 219–227 (2020).
32. Tandon, P. K. & Kakkis, E. D. The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. *Orphanet J. Rare Dis.* **16**, 183 (2021).
33. Perfetto, E. M., Burke, L., Oehrlein, E. M. & Epstein, R. S. Patient-focused drug development: a new direction for collaboration. *Med. Care* **53**, 9–17 (2015).
34. Shapiro, E. G. & Eisengart, J. B. The natural history of neurocognition in MPS disorders: a review. *Mol. Genet. Metab.* **133**, 8–34 (2021).
35. Wijburg, F. A. et al. An observational, prospective, multicenter, natural history study of patients with mucopolysaccharidosis type IIIA. *Mol. Genet. Metab.* **135**, 133–142 (2022).
36. Shapiro, E. G., Eisengart, J. B., Whiteman, D. & Whitley, C. B. Ability change across multiple domains in mucopolysaccharidosis (Sanfilippo syndrome) type IIIA. *Mol. Genet. Metab.* **141**, 108110 (2024).
37. Shapiro, E. G. et al. Quantifying behaviors of children with Sanfilippo syndrome: the Sanfilippo Behavior Rating Scale. *Mol. Genet. Metab.* **114**, 594–598 (2015).
38. Shapiro, E. et al. The neurobehavioral phenotype in mucopolysaccharidosis type IIIB: an exploratory study. *Mol. Genet. Metab. Rep.* **6**, 41–47 (2016).
39. Potegal, M. et al. Mucopolysaccharidosis Type IIIA presents as a variant of Klüver–Bucy syndrome. *J. Clin. Exp. Neuropsychol.* **35**, 608–616 (2013).
40. Shapiro, E. G., Jones, S. A. & Escobar, M. L. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations—neurological signs and symptoms. *Mol. Genet. Metab.* **122S**, 1–7 (2017).
41. Sparrow, S. S., Cicchetti, D. V. & Saulnier, C. A. Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) (Pearson, 2016).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024, corrected publication 2024

Methods

Trial design and oversight

This study was conducted from January 2020 through March 2023 at a single site. The design was developed in partnership with one of the largest Sanfilippo syndrome patient advocacy groups, the Cure Sanfilippo Foundation, which has been involved with multiple international research initiatives. Its chief science officer (author C.O.) served as a co-investigator, enabling integration of patient perspectives in design and study implementation throughout.

Ethics

An independent external data and safety monitor reviewed all data. The trial was performed according to the Declaration of Helsinki. Independent ethics committee approval was obtained from the John F. Wolf, M.D. Human Subjects Committee at the Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center. Participants' legal guardians provided written informed consent. No participant was cognitively able to provide consent or assent.

Study enrollment

Participants were recruited nationwide with the help of the Cure Sanfilippo Foundation and publicly posted study announcements. Participants were screened in the order that they contacted the study. Participant sex was collected from the parent/caregiver. Gender data were not collected. This is due to the severe cognitive deficits in our study population such that they are unable to self-report sex or gender. Sex and/or gender were not considered in the study design. Full inclusion and exclusion criteria are as follows:

Inclusion criteria.

- MPS III diagnosis confirmed by genetic testing.
- ≥ 4 years old.
- Patient or parent/legal guardian were able and willing to provide informed consent. For patients 7–17 years of age, assent was provided when cognitively possible.
- If on genistein, a stable dose for 6 months was required before enrollment.
- If on melatonin or other sleep medications, stable doses were required for the past 3 months.
- Two of the following criteria were met:
 1. CSHQ Total score ≥ 41 .
 2. SBRS Cluster or Domain score ≥ -2 s.d. of mean for age group.
 3. The presence of significant MPS III-related CNS impairment or behavioral disturbances.
 4. NCCPC-R Total Score ≥ 7 .
 5. Seizure disorder thought to be due to MPS III-related disease changes, requiring use of regular medication.
 6. Presence of a movement disorder.

OR one of the following criteria was met:

1. Previous participation in a gene/cell therapy or enzyme-restorative clinical trial.
2. Previous exclusion from a gene/cell therapy or enzyme-restorative clinical trial.
3. Functional age as measured by the Vineland Adaptive Behavior Scales (Second or Third Edition^{41,42}) was ≤ 0.5 chronological age. The Vineland was recommended at two international consensus conferences^{30,43} to assess daily functioning in MPS and has been shown to be an appropriate measure of functional level in MPS III (refs. 1,35,36,44).

Exclusion criteria.

- Currently enrolled in another clinical treatment trial.
- Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.

- Use of any of the following therapies before enrollment:
 - Narcotic analgesics (within 24 h)
 - Tocilizumab, dapsone or mycophenolate mofetil (within 3 weeks)
 - Etanercept, leflunomide, thalidomide or cyclosporine or intraarticular, intramuscular, intravenous or oral administration of glucocorticoids (within 4 weeks)
 - Intravenous immunoglobulin (IVIG), adalimumab or methotrexate (within 8 weeks).
 - Infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil (within 12 weeks)
 - Rituximab (within 26 weeks)
- Live vaccines within 1 month before enrollment.
- Known presence or suspicion of active, chronic or recurrent serious bacterial, fungal or viral infections, including tuberculosis (TB), HIV infection or hepatitis B or C infection.
- Clinical evidence of liver disease or liver injury as indicated by the presence of abnormal liver tests.
 - AST or ALT $> 5 \times$ upper limit of normal (ULN) or
 - AST or ALT $> 3 \times$ ULN accompanied by elevated bilirubin $> 2 \times$ ULN.
- Severe renal function impairment (estimated creatinine clearance $< 30 \text{ ml min}^{-1} 1.73 \text{ m}^{-2}$).
- Neutropenia (defined as absolute neutrophil count (ANC) $< 1,200$ cells per microliter).
- History of malignancy.
- Hypersensitivity to *Escherichia coli*-derived proteins or any components of anakinra.
- Pregnant or lactating women.
- Current active infection.
- History of serious opportunistic infection (for example, bacterial (Legionella and Listeria); TB; invasive fungal infections; or viral, parasitic and other opportunistic infections).
- Positive TB skin test, positive QuantiFERON-TB Gold test, positive chest X-ray or a recent exposure to TB.
- Live vaccine exposure that would be required to occur during the study.
- Any other social or medical condition that the investigator thinks would pose a substantial hazard to the participant if the investigational therapy were initiated or be detrimental to the study.

Dosing

Anakinra SC was administered at 100 mg or 200 mg SC once daily. The starting dose (100 mg SC once daily) is the dose level recommended for adult rheumatoid arthritis. The dose escalation was within the range of the recommended dose in NOMID. Non-weight-based dosing was based on pharmacokinetic data in 22 pediatric patients with systemic-onset juvenile idiopathic arthritis in the age range of 2–17 years⁴⁵.

Dose was increased to 200 mg SC once daily, with a maximum dose limit of $8 \text{ mg kg}^{-1} \text{ d}^{-1}$ at week +8 or week +16, if the change in at least one of the two most bothersome outcomes selected by the parents/guardians at day 1 had not improved by $\geq$ the MCID. The exception was the disordered movement 7-d log, which did not have a calculatable MCID until the dataset was complete; therefore, dose was increased if there was worsening or no change in either the Duration or Severity as described below. After increase at week +8, if the MCID was again not achieved after eight sustained weeks on the maximum trial dose of 200 mg (maximum dose $8 \text{ mg kg}^{-1} \text{ d}^{-1}$), treatment with anakinra could be discontinued after a review and discussion between the study principal investigator and the participant's parent(s) of their child's individual results from all outcome measures.

For example:

- At week +8, if a participant had not improved in the chosen items, then the dose was increased to 200 mg SC daily.
- At week +8, if a subject had improved, then the dose stayed at 100 mg SC daily. However, if this individual then had worsening of the two most bothersome outcomes from week +8 to week +16, after improving from day 1 to week +8, the dose was increased to 200 mg SC daily at that point (that is, increase at week +16 after not increasing at week +8).

Dose was decreased by 50 mg SC once daily at any time throughout the study if a participant developed any of the following:

- Neutropenia <1,200 cells per microliter persistent for ≥ 2 weeks (decreased from 1,500 cells per microliter on 11 January 2021)
- Thrombocytopenia $<50 \times 10^9$ platelets per liter persistent for ≥ 2 weeks
- Mild/moderate hypersensitivity reactions, including urticaria, rash and pruritis
- Common Terminology Criteria for Adverse Events grade 3 AE

Anakinra was stopped if the AE above did not resolve within 2 weeks of decreasing the dose by 50 mg SC once daily. Anakinra was restarted at 0.5 times the last dose administered once the AE was resolved. If the AE recurred with restarting anakinra, it was discontinued, and the participant was monitored per protocol.

Outcomes

Primary outcomes. The primary safety and tolerability endpoint (phase 1) was defined as the occurrence of AEs and SAEs. The primary dosing (phase 2) endpoint was the percent of participants who required an increase in anakinra dose from 100 mg SC daily to 200 mg SC daily at week 8 or week 16.

Secondary outcomes

MDRI. The MDRI was composed of an SBRS and standardized ratings of sleep habits (CSHQ), fatigue (PROMIS–Fatigue Parent Proxy Custom Short Form), pain (NCCPC-R) and parenting stress (APSI) as well as parent tracking of disordered movement (disordered movement 7-d log). The MCID, used to determine improvement (>1 MCID in direction of improvement), worsening (>1 MCID in direction of worsening) or no change (<1 MCID in either direction) on the MDRI, was defined for each outcome based on previous reports in the literature when available or the change during the first 8-week observation period when not available (that is, disordered movement log).

Additional secondary outcomes were mean change in each survey included in the MDRI, described below, followed by a description of the ICR.

Sleep. *CSHQ (paper form).* The CSHQ is a parent questionnaire that has been used in many studies to examine both behavioral-based and medical-based sleep problems in children. It yields a total score and eight subscale scores: (1) Bedtime Resistance, (2) Sleep Onset Delay, (3) Sleep Duration, (4) Sleep Anxiety, (5) Night Wakings, (6) Parasomnias, (7) Sleep-Disordered Breathing and (8) Daytime Sleepiness. It has been validated in multiple groups, including community children and children diagnosed with sleep disorders, development delay and/or autism^{46,47}.

Scoring: Higher scores indicate more significant and frequent symptoms. Each item is scored on a scale of 1–3, and a total sleep disturbances score may range from 33 to 99.

MCID = 3.2 based on 469 children aged 4–10 years⁴⁶.

Behavior. *SBRS (paper form).* The SBRS is a 68-item questionnaire developed to assess the behavioral phenotype of children with MPS III and its progression over time^{37,48}. The SBRS has been validated in

Sanfilippo samples³⁷ and correlated with biomarkers^{37–39}. There are 15 ‘domain scales’ that rate the frequency of symptoms related to orality, movement/activity, attention/self-control, emotional function and social interaction. In addition, 12 of the 15 domain scales are grouped into four abnormality clusters: Movements, Lack of Fear, Social/Emotional Dysfunction and Executive Dysfunction. Two domain scales are recommended by the test developers to be analyzed separately: Orality and Mood/Anger/Aggression.

Scoring: Higher scores indicate higher frequency of symptoms. Each item is scored on a scale of 0–6. A mean score is calculated for each SBRS domain and cluster, and then an average is taken for the SBRS Total score. The mean scores were standardized using the mean and standard deviation from a cohort of patients with MPS III, ages 81–220 months⁴⁸. This reference cohort was chosen to best match the age distribution of our participants.

MCID (SBRS Total mean score only) = 0.57 based on 18 children with Sanfilippo syndrome aged 6–23 years³⁸.

Pain. *NCCPC-R (paper form).* The NCCPC-R is validated for measuring pain in children with severe cognitive impairments^{49,50}. It includes seven scales that measure vocal, social, facial, activity, body and limbs, physiological and eating/sleeping indicators of pain. A combined total score for pain was calculated.

Scoring: Higher scores indicate greater pain. Each item is scored on a scale of 0–3, and a total pain score may range from 0 to 99.

MCID = 4.6 based on 57 non-verbal children aged 3–18 years⁵⁰.

Parent fatigue. *PROMIS Fatigue–Parent Proxy Custom Short Form (paper form).* Per PROMIS guidance, we selected the 10 most relevant questions for parents of children with MPS III from the PROMIS Parent Proxy Fatigue item bank to make a customized PROMIS Fatigue–Parent Proxy Custom Short Form. Customized short forms were scored using this online scoring service: https://www.assessmentcenter.net/ac_scoringervice.

Scoring: Higher scores indicate more fatigue. Each item is scored on a scale of 1–5, and a total fatigue score may range from 10 to 50.

MCID = 2.2 based on 85 parents/guardians of children with cancer, sickle cell disease, nephrotic syndrome or asthma⁵¹.

Parenting stress. *APSI (paper form).* The APSI was developed based on many interviews of parents of children with autism. We selected it because of findings that many children with MPS III develop autism or autistic symptoms during the course of their disease^{38,52}. The APSI items fall into three categories: the core social disability, difficult-to-manage behaviors and physical issues. The APSI measures how much stress the parents are experiencing related to these three categories. The overall APSI scale score has been validated for parents of children with autism and other developmental disabilities⁵³.

Scoring: Higher scores indicate greater parenting stress. Each item is scored on a scale of 0–5, and a total APSI score may range from 0 to 99.

MCID = 0.5 based on 139 neurotypical children aged 2–6 years⁵³.

Disordered movement. *Disordered movement 7-d log (paper form).* Duration, severity and type (for example, dystonia, chorea and other) of movement abnormality were reported by the caregiver in real time for 1 week at a time in a survey.

Duration was quantified as:

- Occasional ($<25\%$ of the time) = 1
- Intermittent (25–50% of the time) = 2
- Frequent (50–75% of the time) = 3
- Constant ($>75\%$ of the time) = 4

Severity was quantified as:

- The movement has interfered less with my child’s daily activities = 1

- No change in the severity of the abnormal movement = 2
- The movement has interfered more with my child's daily activities = 3

Scoring: Higher scores indicate increased duration and/or severity of disordered movement. Average was taken of the 7-d average Duration score and the 7-d average Severity score. The total score may range from 1 to 7.

MCID = 0.14 based on change in total movement score over the first 8 weeks of observation in this study, before treatment with anakinra ($n = 23$).

ICR (paper form). The ICR allowed a caregiver to choose five out of 15 items that they felt were the most impactful. Items chosen based on previous caregiver preference work⁵⁴ were sleep disturbances, hyperactivity, frustration/impulse control/aggressive behaviors, feeding, anxiety, unhappiness, communication, social deficits, digestive issues and toileting, pain, illness/vulnerability to illness, fatigue, seizure, mobility and gait. The five items selected by the caregiver were then maintained for longitudinal ratings throughout the trial.

The caregiver rated each of these outcomes on a five-point Likert scale as follows:

- 0 = Not stressful
- 1 = Sometimes creates stress
- 2 = Often creates stress
- 3 = Very stressful on a daily basis
- 4 = So stressful sometimes we feel we cannot cope

Scoring: Higher scores indicate more stress, with a possible range of 0–20 for the total ICR at each assessment.

Screening measure

Vineland Adaptive Behavior Scales, Second or Third Edition^{41,42} (Second Edition: paper form; Third Edition: paper or electronic form). The frequency that a person shows independence in age-typical life activities is rated by a caregiver as occurring never, sometimes (or partially) and usually. Domains of Communication, Daily Living Skills and Socialization are combined for an Adaptive Behavior Composite.

Scoring: Norm-referenced scores (population mean $\pm$ s.d.) are 100 ± 15 . Scores within one standard deviation of the mean—that is, 85–115—are in the ‘average’ range, whereas 70–84 is below average, and less than 70 is impaired. Age-equivalent scores are available from a lookup table in the back of the Vineland manual. The average of all subdomain age equivalents was divided by chronological age to determine if a child was <0.5 .

Post hoc measure

Immunophenotyping. Phenotypic characterization of immune cell lineages was performed from whole blood cells (myeloid cells, T cells, T regulatory cells and B regulatory cells) at each study visit to measure immunologic effects of treatment. Whole blood cells were first stained with specific antibodies and then fixed to lyse red blood cells, as previously described⁵⁵. Identification of blood cell subtypes was performed as follows. In brief, monocytes were gated within the myeloid cell population identified by excluding B cells (CD19-APC-Cy7⁺ cells, Thermo Fisher Scientific, 561743) and T cells (CD3-PE⁺ cells, BD Biosciences, BDB555333) from the whole blood population. Within the myeloid population, natural killer (NK) cells were excluded using CD56⁺ cells (CD56-FITC⁺ and CD14⁺ Alexa 647 cells, 340410 and 562690, respectively). Subsequently, neutrophils were identified as bright CD16-PerCP-Cy5.5⁺ (BD Biosciences, 560717) high side scatter (SSC) cells. Monocytes were identified as CD14⁺ and CD16⁺ cells. CD4-APC-Cy7⁺ cells (BD Biosciences, 566319) and CD8-PE-Cy7⁺ cells (BD Biosciences, 335787) were gated within the CD3⁺ cells of the whole blood, excluding B cells (CD19-APC⁺ cells, BD Biosciences, 555415), and T cells were gated as CD19⁺ cells. The antibodies were diluted at a ratio

of 1.5:200 and then titrated against blood samples to assess reactivity and binding efficiency. Flow cytometry data were acquired using a BD FACS Aria III using FACSDiva version 9.0.1 and post-analyzed using FlowJo version 10.8.1.

Statistical analysis

The safety population, used for the safety and tolerability outcomes, included all participants who received at least one dose of anakinra during the study. The efficacy analysis population included all participants assigned to treatment with anakinra regardless of whether they completed the treatment and/or all scheduled study visits (that is, intent-to-treat analysis). This was done to provide the most conservative estimate of treatment effects.

The number of participants for the study was determined by feasibility rather than statistical power owing to the rarity of MPS III. Categorical outcomes were summarized using frequencies and percentages, and continuous outcomes were summarized using means and standard deviations or medians and interquartile ranges.

Mixed models for repeated measures were used to estimate and assess changes over time, with time serving as a within-subject factor. We employed the unstructured covariance structure for the repeated measures and presented the least-squares means along with 95% CIs. Residual analyses were conducted, including studentized and Pearson residuals, and compared to the standard normal quantile–quantile plot to assess the model's adherence to its underlying assumptions, and no serious violations were detected. Sensitivity analyses were performed using imputation for missing data and a non-parametric test for all six MDRI outcomes. Imputation used the last observation carried forward (LOCF) method (Fig. 3). LOCF is commonly used in clinical trials and longitudinal studies to impute missing values, especially when the missing data do not follow a discernible pattern. Given the limited sample size, identifying a specific pattern of missing data and applying multiple imputation methods was not a viable option due to the lack of data to serve as predictors within a regression model for such imputation. The Wilcoxon signed-rank test was used for non-parametric tests. The association between immunophenotype and the number of improvements and worsenings in MDRI was assessed using Spearman's rank-based correlation coefficient.

Data were analyzed using SAS version 9.4 (SAS Institute) by author Y.P. All tests were two-tailed, and $P < 0.05$ was considered statistically significant. No adjustment was made for multiplicity in the analyses. Therefore, the reported P values and CIs should be interpreted with caution and discussed with recognition of inflated family-wise type I error rate.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The de-identified individual participant data that underlie the results reported in this article (including text, tables and figures) are included in Supplementary Data File 1. Source data are provided with this paper.

References

42. Sparrow, S. S., Cicchetti, D. & Balla, D. A. Vineland Adaptive Behavior Scales, Second Edition (Vineland-II). <https://doi.org/10.1037/t15164-000> (2005).
43. van der Lee, J. H. et al. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure. *Mol. Genet. Metab.* **121**, 70–79 (2017).
44. Truxal, K. V. et al. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: implications for clinical trial design. *Mol. Genet. Metab.* **119**, 239–248 (2016).

45. Urien, S. et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. *BMC Pharmacol. Toxicol.* **14**, 40 (2013).
46. Owens, J. A., Spirito, A. & McGuinn, M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. *Sleep* **23**, 1043–1051 (2000).
47. Goodlin-Jones, B. L., Sitnick, S. L., Tang, K., Liu, J. & Anders, T. F. The Children's Sleep Habits Questionnaire in toddlers and preschool children. *J. Dev. Behav. Pediatr.* **29**, 82–88 (2008).
48. Shapiro, E., Potegal, M., Rudser, K. & Delaney, K. Revised Manual for the Sanfilippo Behavior Rating Scale (SBRs). (2014).
49. Breau, L. M., McGrath, P. J., Camfield, C. S. & Finley, G. A. Psychometric properties of the non-communicating children's pain checklist-revised. *Pain* **99**, 349–357 (2002).
50. Breau, L. M. et al. Relation between pain and self-injurious behavior in nonverbal children with severe cognitive impairments. *J. Pediatr.* **142**, 498–503 (2003).
51. Thissen, D. et al. Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. *Qual. Life Res.* **25**, 13–23 (2016).
52. Rumsey, R. K. et al. Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. *J. Pediatr.* **164**, 1147–1151 (2014).
53. Silva, L. M. T. & Schalock, M. Autism parenting stress index: initial psychometric evidence. *J. Autism Dev. Disord.* **42**, 566–574 (2012).
54. O'Neill, C., Porter, K., Drake, E. & Peay, H. L. Meaningful treatment outcomes for Sanfilippo syndrome: a study of caregiver preferences and prioritization. *Mol. Genet. Metab.* **126**, S112–S113 (2019).
55. Hasan, M. et al. Semi-automated and standardized cytometric procedures for multi-panel and multi-parametric whole blood immunophenotyping. *Clin. Immunol.* **157**, 261–276 (2015).

Acknowledgements

We thank the participants and their families for their participation in the study. We also thank the staff in the CTSI Clinical and Translational Research Center at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Anakinra (Kineret) was provided free of charge by Swedish Orphan Biovitrum AB (publ) (Sobi) under an Investigator Initiated Study Agreement. Sobi was not involved in the design or conduct of the study, data collection and analysis or preparation of the manuscript. Funding for this study was provided by the Cure Sanfilippo Foundation (grant no. 031834-01-00 LEP).

Author contributions

L.E.P.: conceptualization, data curation, funding acquisition, investigation, methodology, project administration, resources, supervision, visualization, writing—original draft and writing—review

and editing. A.C.: conceptualization, investigation, methodology, project administration and writing—review and editing. Y.P.: data curation, formal analysis and writing—review and editing. A.L.: investigation, project administration and writing—review and editing. A.M.G.: investigation, data curation, project administration and writing—review and editing. J.A.: investigation and writing—review and editing. G.B.: writing—review and editing. M.I.: investigation, resources, methodology, project administration and writing—review and editing. C.O.: conceptualization, funding acquisition, methodology and writing—review and editing. J.B.E.: conceptualization, methodology, visualization, writing—original draft and writing—review and editing.

Competing interests

L.E.P. has research grants/contracts with BioMarin and Takeda; is a consultant for BioMarin, Lysogene and Denali Therapeutics; participated on a data safety monitoring board or advisory board for RegenxBio and Sangamo; and has received honoraria from BioMarin. A.H.C. has a research grant/contract with Takeda. J.A. and G.B. have research grants/contracts from the Cure Sanfilippo Foundation. C.O. is an employee of the Cure Sanfilippo Foundation, a non-profit organization; has served as a consultant for Denali Therapeutics, JCR Pharmaceuticals and Lysogene; and participated on a data safety monitoring board or advisory board for BioMarin, Lysogene and Ultragenyx. J.B.E. has research grants/contracts with Orchard Therapeutics, Prevail and Lysogene; received consulting fees from Denali Therapeutics, JCR Pharmaceuticals, Novel Pharma, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Sumitomo Pharma Co., Ltd. and Takeda; and received honoraria from Takeda. The remaining authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-024-03079-3>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-024-03079-3>.

Correspondence and requests for materials should be addressed to Lynda E. Polgreen.

Peer review information *Nature Medicine* thanks Melanie Calvert, Paul Harmatz, Mats Pihlgård and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Sonia Muliyil, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | Change in the Individual Clinical Response (ICR) before, during and after treatment with anakinra. Treatment period indicated by grey box (Week Zero to Week 36). The black line graph with circle symbols shows the observed LSMs with 95% confidence intervals for patients with available data (observed) over time. The imputed LSMs for the prespecified sensitivity analysis are plotted as grey lines with square symbols. A return of

symptoms after eight weeks off treatment, seen by the upward slope to Week 44, suggests the reduction of symptoms from Weeks Zero to 36 were not part of the natural disease course. There was no statistically significant difference in ICR between Week 44 and Day One. All statistical tests were two-sided, including the Wald test with 23 degrees of freedom from the mixed model. No adjustment was made for the multiple comparison.

Extended Data Table 1 | Incidence of and event rates of treatment-emergent AEs by preferred term

	Overall population (N=23)				On treatment (N=23)				Post-treatment* (N=16)			
	Incidence		Event rate		Incidence		Event rate		Incidence		Event rate	
Adverse Event	N	%	N	rate	N	%	N	rate	N	%	N	rate
Subject with any serious adverse event†	3	13%	3	0.13	2	9%	2	0.09	1	4%	1	0.04
Subject with any adverse event	22	96%	460	20.00	22	96%	408	17.74	15	65%	52	2.26
Injection Site Adverse Events:												
Injection site reaction (any)					18	78%	326	14.17				
Injection site erythema					17	74%	165	7.17				
Injection site swelling					10	43%	52	2.26				
Injection site bruising					5	22%	41	1.78				
Injection site itching					3	13%	65	2.83				
Injection site bleeding					3	13%	3	0.13				
Non-injection site adverse events:												
Upper respiratory infection	9	39%	12	0.52	7	30%	8	0.35	4	17%	4	0.17
Constipation	7	30%	9	0.39	4	17%	5	0.22	4	17%	4	0.17
Agitation	6	26%	6	0.26	4	17%	4	0.17	2	9%	2	0.09
Neutropenia	6	26%	10	0.43	6	26%	9	0.39	1	4%	1	0.04
COVID19 - mild symptoms	5	22%	5	0.22	5	22%	5	0.22	0	0%	0	0.00
Diarrhea	5	22%	5	0.22	4	17%	4	0.17	1	4%	1	0.04
Acute otitis media	4	17%	5	0.22	2	9%	2	0.09	2	9%	3	0.13
Thrombocytopenia	4	17%	5	0.22	4	17%	4	0.17	1	4%	1	0.04
Rash	3	13%	3	0.13	1	4%	1	0.04	2	9%	2	0.09
Seizures	3	13%	4	0.17	1	4%	1	0.04	2	9%	3	0.13
Stiffness in arms and legs	3	13%	3	0.13	1	4%	1	0.04	2	9%	2	0.09
Bronchitis	2	9%	2	0.09	2	9%	2	0.09	0	0%	0	0.00
Cough	2	9%	3	0.13	0	0%	0	0.00	2	9%	3	0.13
Excessive drooling	2	9%	2	0.09	2	9%	2	0.09	0	0%	0	0.00
Fatigue	2	9%	2	0.09	0	0%	0	0.00	2	9%	2	0.09
Headaches	2	9%	2	0.09	0	0%	0	0.00	2	9%	2	0.09
Rhinorrhea	2	9%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Abdominal pain	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Acrocyanosis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Acute gastroenteritis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Aspiration pneumonia	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Bacterial vaginosis	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Hypercholesterolemia	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Cutaneous Infection - hand	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Dental caries w/ abscess	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Diaper rash	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Dysmenorrhea	1	4%	2	0.09	1	4%	2	0.09	0	0%	0	0.00
Dysuria	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Eczema	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Epistaxis	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Epstein-Barr virus infection	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Fall	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Fever - unknown etiology	1	4%	2	0.09	1	4%	2	0.09	0	0%	0	0.00
Gait abnormality	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Gastritis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Gastroenteritis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Gastroesophageal reflux disease	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Hip pain	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Hypertransaminasemia	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Hypoglycemia - fasting	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Hypokalemia	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Influenza	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Irritable bowel disease	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Laceration of left bicep muscle	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Left leg pain	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Metabolic acidosis	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Operculitis	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Oral candidiasis	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Oral herpes	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Periodic limb movement during sleep	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Pharyngitis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Pneumonia - viral	1	4%	2	0.09	1	4%	2	0.09	0	0%	0	0.00
Poor balance	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Sinusitis	1	4%	2	0.09	0	0%	0	0.00	1	4%	2	0.09
Strep pharyngitis/Scarlet fever	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Thrombocytopenia	1	4%	2	0.09	1	4%	1	0.04	1	4%	1	0.04
Tinea corporis	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Tooth infection	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Uncontrolled giggling-possible gelastic seizures	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Upper gastrointestinal hemorrhage	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Vaginal candidiasis	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04
Vitamin D deficiency	1	4%	1	0.04	1	4%	1	0.04	0	0%	0	0.00
Vomiting	1	4%	1	0.04	0	0%	0	0.00	1	4%	1	0.04

*AEs occurring either after early drug discontinuation for participants who continued in the study off treatment and after discontinuation of treatment at week 36 to week 48.

†No treatment related serious adverse events.

Extended Data Table 2 | Estimated least-square means (LSMs) in SBRS clusters (Movements, Social/Emotional Dysfunction, Lack of Fear and Executive Dysfunction) and domains (Orality and Mood/Anger/Aggression) before, during and after treatment with anakinra and differences in LSMs from screening and from day 1

Outcome	Time	N	LSM	SE	Change (Δ) From Screening							Change (Δ) From Day 1				
					LSM Lower 95% CI	LSM Upper 95% CI	LSM Δ	LSM Δ SE	LSM Δ Lower 95% CI	LSM Δ Upper 95% CI	LSM Δ P-value	LSM Δ	LSM Δ SE	LSM Δ Lower 95% CI	LSM Δ Upper 95% CI	LSM Δ P-value
Movement	Screening	24	1.60	0.32	0.94	2.26						-0.04	0.27	-0.60	0.51	0.8752
	Day 1	23	1.64	0.27	1.09	2.20	0.04	0.27	-0.51	0.60	0.8752					
	Week 8	21	1.43	0.23	0.95	1.91	-0.17	0.21	-0.60	0.26	0.4180	-0.21	0.19	-0.60	0.17	0.2629
	Week 16	17	1.33	0.26	0.80	1.86	-0.27	0.26	-0.81	0.27	0.3105	-0.31	0.20	-0.72	0.09	0.1225
	Week 36	16	0.97	0.21	0.52	1.41	-0.63	0.33	-1.31	0.05	0.0663	-0.68	0.24	-1.17	-0.19	0.0089
	Week 44	16	1.40	0.29	0.79	2.01	-0.20	0.31	-0.84	0.44	0.5260	-0.24	0.33	-0.92	0.44	0.4698
Lack of Fear	Week 36-44	16	-0.43	0.27	-0.99	0.12					0.1189 ^A					0.1189 ^A
	Screening	24	0.85	0.28	0.26	1.43						-0.23	0.24	-0.74	0.27	0.3464
	Day 1	23	1.08	0.24	0.58	1.58	0.23	0.24	-0.27	0.74	0.3464					
	Week 8	21	1.00	0.20	0.59	1.42	0.16	0.26	-0.38	0.69	0.5511	-0.08	0.13	-0.35	0.20	0.5690
	Week 16	17	0.93	0.23	0.45	1.41	0.08	0.27	-0.48	0.64	0.7719	-0.15	0.17	-0.50	0.19	0.3666
	Week 36	16	1.10	0.24	0.60	1.61	0.26	0.27	-0.30	0.81	0.3544	0.02	0.14	-0.26	0.30	0.8762
Social/Emotional Dysfunction	Week 44	16	1.04	0.22	0.59	1.50	0.19	0.28	-0.38	0.77	0.4921	-0.04	0.17	-0.39	0.31	0.8147
	Week 36-44	16	0.06	0.16	-0.28	0.40					0.7117 ^A					0.7117 ^A
	Screening	24	2.63	0.58	1.42	3.84						-0.53	0.32	-1.20	0.14	0.1168
	Day 1	23	3.16	0.57	1.97	4.35	0.53	0.32	-0.14	1.20	0.1168					
	Week 8	21	2.88	0.61	1.63	4.14	0.25	0.34	-0.45	0.96	0.4623	-0.28	0.33	-0.95	0.40	0.4091
	Week 16	17	2.36	0.58	1.16	3.56	-0.27	0.38	-1.06	0.52	0.4862	-0.80	0.36	-1.54	-0.06	0.0348
Executive Dysfunction	Week 36	16	1.96	0.54	0.84	3.09	-0.66	0.53	-1.77	0.44	0.2254	-1.19	0.49	-2.21	-0.17	0.0237
	Week 44	16	2.82	0.65	1.47	4.17	0.19	0.49	-0.83	1.21	0.7046	-0.34	0.46	-1.30	0.62	0.4707
	Week 36-44	16	-0.85	0.44	-1.75	0.05					0.0622 ^A					0.0622 ^A
	Screening	24	0.57	0.28	-0.01	1.14						0.04	0.19	-0.34	0.43	0.8222
	Day 1	23	0.52	0.25	0.00	1.05	-0.04	0.19	-0.43	0.34	0.8222					
	Week 8	21	0.14	0.31	-0.51	0.79	-0.42	0.30	-1.05	0.20	0.1750	-0.38	0.32	-1.04	0.28	0.2423
Orality	Week 16	17	0.02	0.27	-0.54	0.58	-0.55	0.29	-1.16	0.06	0.0740	-0.51	0.29	-1.10	0.08	0.0865
	Week 36	16	-0.05	0.31	-0.70	0.60	-0.61	0.43	-1.50	0.27	0.1627	-0.57	0.34	-1.29	0.14	0.0875
	Week 44	16	0.24	0.32	-0.42	0.89	-0.33	0.33	-1.00	0.34	0.3214	-0.29	0.28	-0.87	0.30	0.1104
	Week 36-44	16	-0.29	0.24	-0.78	0.21					0.2428 ^A					0.2428 ^A
	Screening	24	1.06	0.21	0.63	1.49						0.05	0.10	-0.14	0.25	0.5851
	Day 1	23	1.01	0.19	0.61	1.40	-0.05	0.10	-0.25	0.14	0.5851					
Mood/Anger/Aggression	Week 8	21	0.86	0.19	0.46	1.26	-0.20	0.09	-0.39	0.00	0.0470	-0.14	0.04	-0.23	-0.06	0.0019
	Week 16	17	0.82	0.19	0.42	1.21	-0.24	0.12	-0.50	0.01	0.0611	-0.19	0.08	-0.35	-0.03	0.0152
	Week 36	16	0.87	0.22	0.42	1.32	-0.19	0.17	-0.54	0.16	0.2663	-0.14	0.11	-0.36	0.09	0.2137
	Week 44	16	1.15	0.23	0.68	1.62	0.09	0.17	-0.27	0.45	0.6042	0.14	0.12	-0.11	0.40	0.0803
	Week 36-44	16	-0.28	0.11	-0.50	-0.06					0.0151 ^A					0.0151 ^A
	Screening	24	0.00	0.40	-0.82	0.82						0.02	0.21	-0.42	0.47	0.9101
	Day 1	23	-0.02	0.32	-0.69	0.65	-0.02	0.21	-0.47	0.42	0.9101					
	Week 8	21	-0.48	0.31	-1.11	0.15	-0.48	0.22	-0.94	-0.03	0.0368	-0.46	0.20	-0.88	-0.04	0.0333
	Week 16	17	-0.45	0.30	-1.07	0.17	-0.45	0.28	-1.02	0.12	0.1125	-0.43	0.16	-0.77	-0.09	0.0148
	Week 36	16	-0.96	0.25	-1.48	-0.43	-0.96	0.26	-1.49	-0.43	0.0010	-0.94	0.18	-1.30	-0.57	<0.0001
	Week 44	16	-0.16	0.40	-0.98	0.66	-0.16	0.33	-0.84	0.52	0.6271	-0.14	0.26	-0.68	0.41	0.6053
	Week 36-44	16	-0.80	0.24	-1.30	-0.30					0.0032 ^A					0.0032 ^A
^ SM p-value for change from Week 36 to Week 44. LSM, Standard Error (SE), and P-value are based on the mixed model for the repeated measures using time as a fixed within subject factor.																

^ALSM p-value for change from Week 36 to Week 44. LSM, Standard Error (SE), and P-value are based on the mixed model for the repeated measures using time as a fixed within subject factor.

All statistical tests were two-sided. No adjustment was made for the multiple comparison.

Extended Data Table 3 | Descriptive statistics of change in SBRS clusters (Movements, Social/Emotional Dysfunction, Lack of Fear and Executive Dysfunction) and domains (Orality and Mood/Anger/Aggression) during and after treatment with anakinra

Outcome	Time	N	Median	Q ₁ [^]	Q ₃ [^]	Minimum	Maximum	Range	P-value [†]
Movement	Day1 to Week 8	21	0.0	-0.3	0.4	-0.7	3.0	3.7	0.5276
	Day1 to Week 16	17	0.1	-0.2	0.7	-1.1	1.9	3.0	0.3348
	Day1 to Week 36	16	0.6	0.0	1.0	-1.2	2.6	3.8	0.0136
	Week 36 to Week 44	16	0.0	-0.8	0.3	-2.7	1.5	4.2	0.4406
	Day 1 to Week 44	16	0.1	-0.3	0.9	-2.0	4.0	6.0	0.3231
Lack of Fear	Day1 to Week 8	21	0.0	-0.4	0.5	-1.7	1.1	2.8	0.5243
	Day1 to Week 16	17	0.2	0.0	0.5	-1.9	1.5	3.4	0.0499
	Day1 to Week 36	16	-0.2	-0.4	0.4	-1.0	1.0	2.0	0.7507
	Week 36 to Week 44	16	0.0	-0.4	0.7	-1.1	1.1	2.2	0.5352
	Day 1 to Week 44	16	0.1	-0.4	0.6	-1.3	1.1	2.4	0.6132
Social/Emotional Dysfunction	Day1 to Week 8	21	-0.2	-0.7	1.0	-2.1	4.1	6.2	0.7245
	Day1 to Week 16	17	0.5	0.0	2.2	-1.9	2.9	4.8	0.0396
	Day1 to Week 36	16	1.5	0.0	2.5	-2.6	4.7	7.3	0.0222
	Week 36 to Week 44	16	-0.5	-1.4	0.2	-4.5	2.4	6.9	0.1202
	Day 1 to Week 44	16	0.2	-0.2	1.3	-4.5	4.1	8.6	0.1539
Executive Dysfunction	Day1 to Week 8	21	0.0	-0.5	0.9	-2.0	5.3	7.3	0.5088
	Day1 to Week 16	17	0.3	-0.2	0.6	-1.5	4.9	6.5	0.3093
	Day1 to Week 36	16	0.5	0.1	0.8	-2.2	5.3	7.5	0.0577
	Week 36 to Week 44	16	-0.4	-0.9	0.4	-2.3	1.7	4.0	0.1551
	Day 1 to Week 44	16	0.1	-0.2	0.5	-1.1	5.3	6.4	0.6808
Orality	Day1 to Week 8	21	0.1	0.1	0.2	-0.2	0.7	0.9	0.0007
	Day1 to Week 16	17	0.1	-0.1	0.3	-0.2	0.8	1.0	0.1312
	Day1 to Week 36	16	0.1	-0.1	0.3	-0.3	1.2	1.5	0.0460
	Week 36 to Week 44	16	-0.3	-0.5	-0.1	-1.0	0.9	1.9	0.0087
	Day 1 to Week 44	16	0.0	-0.4	0.2	-1.1	0.8	1.9	0.6288
Mood/Anger/Aggression	Day1 to Week 8	21	0.4	0.0	0.8	-1.4	2.4	3.8	0.0418
	Day1 to Week 16	17	0.4	-0.2	1.2	-0.8	1.6	2.4	0.0333
	Day1 to Week 36	16	0.9	0.5	1.5	-0.4	2.0	2.4	0.0004
	Week 36 to Week 44	16	-0.3	-1.5	0.0	-2.6	0.4	3.0	0.0127
	Day 1 to Week 44	16	0.1	-0.4	0.9	-1.6	2.4	4.0	0.5313
[^] Q ₁ = 25 th Percentile; Q ₃ = 75 th Percentile Range = Maximum - Minimum [†] Based on the Signed Rank test. No adjustment made for the multiple testing.									

Extended Data Table 4 | Estimated least-square means (LSMs) in SBRS total score, CSHQ, NCCPC-R, PROMIS Fatigue, APSI, 7-d disordered movement log and the ICR before, during and after treatment with anakinra and differences in LSMs from screening and from day 1

Outcome	Time	N	LSM	SE	LSM Lower 95% CI	LSM Upper 95% CI	Change (Δ) From Screening					Change (Δ) From Day 1				
							LSM Δ	LSM Δ SE	LSM Δ Lower 95% CI	LSM Δ Upper 95% CI	LSM Δ P-value	LSM Δ	LSM Δ SE	LSM Δ Lower 95% CI	LSM Δ Upper 95% CI	LSM Δ P-value
CSHQ	Screening	24	49.04	1.69	45.55	52.54						1.87	1.29	-0.79	4.53	0.16
	Day 1	23	47.17	1.87	43.29	51.05	-1.87	1.29	-4.53	0.79	0.16					
	Week 8	21	46.00	1.54	42.81	49.19	-3.04	0.80	-4.70	-1.38	0.0009	-1.17	1.05	-3.35	1.00	0.2750
	Week 16	17	46.34	1.90	42.40	50.27	-2.71	1.26	-5.31	-0.10	0.0422	-0.84	1.35	-3.62	1.95	0.5397
	Week 36	16	46.50	2.25	41.84	51.16	-2.54	1.99	-6.66	1.57	0.2140	-0.67	1.74	-4.27	2.93	0.7029
	Week 44	16	47.76	1.57	44.51	51.01	-1.28	1.00	-3.36	0.80	0.2147	0.59	1.24	-1.98	3.16	0.6395
SBRS Total	Week 36-44	16	-1.26	1.46	-4.28	1.76					0.3969 ^A					0.3969 ^A
	Screening	24	1.12	0.24	0.62	1.61						-0.11	0.13	-0.38	0.16	0.4077
	Day 1	23	1.23	0.22	0.77	1.68	0.11	0.13	-0.16	0.38	0.4077					
	Week 8	21	0.98	0.23	0.51	1.45	-0.14	0.13	-0.41	0.13	0.3050	-0.25	0.13	-0.52	0.02	0.0683
	Week 16	17	0.84	0.21	0.41	1.27	-0.27	0.13	-0.59	0.04	0.0827	-0.39	0.12	-0.62	-0.15	0.0028
	Week 36	16	0.63	0.21	0.20	1.07	-0.49	0.13	-0.97	-0.01	0.0475	-0.60	0.19	-0.99	-0.20	0.0052
NCCPC-R	Week 44	16	1.04	0.25	0.52	1.57	-0.07	0.13	-0.47	0.33	0.7072	-0.18	0.20	-0.60	0.23	0.3720
	Week 36-44	16	-0.41	0.18	-0.78	-0.05					0.0284 ^A					0.0284 ^A
	Screening	24	21.67	2.65	16.18	27.16						-0.43	2.24	-5.07	4.21	0.8495
	Day 1	23	22.10	3.19	15.51	28.69	0.43	2.24	-4.21	5.07	0.8495					
	Week 8	21	18.07	2.46	12.98	23.16	-3.60	1.77	-7.25	0.05	0.0531	-4.03	2.53	-9.26	1.20	0.1243
	Week 16	17	19.19	2.95	13.09	25.30	-2.47	1.88	-6.36	1.42	0.2016	-2.90	2.23	-7.51	1.71	0.2054
APSI - short	Week 36	16	18.54	2.98	12.57	24.70	-3.13	2.52	-8.34	2.08	0.2268	-3.56	2.75	-9.25	2.12	0.2079
	Week 44	16	21.32	3.05	15.00	27.64	-0.35	2.83	-6.21	5.52	0.9042	-0.78	2.52	-6.00	4.45	0.7814
	Week 36-44	16	-2.79	2.62	-8.21	2.64					0.2969 ^A					0.2969 ^A
	Screening	24	15.54	1.37	12.70	18.38						1.21	0.96	-0.77	3.19	0.2186
	Day 1	23	14.33	1.53	11.16	17.50	-1.21	0.96	-3.19	0.77	0.2186					
	Week 8	21	13.24	1.26	10.64	15.85	-2.30	0.93	-4.23	-0.37	0.0216	-1.09	1.11	-3.38	1.21	0.3367
PROMIS Fatigue - short	Week 16	17	11.41	1.22	8.88	13.93	-4.14	1.25	-6.73	-1.54	0.0032	-2.93	1.08	-5.17	-0.69	0.0127
	Week 36	16	10.53	0.90	8.66	12.40	-5.01	1.43	-7.97	-2.05	0.0019	-3.80	1.43	-6.76	-0.84	0.0142
	Week 44	16	14.23	1.53	11.06	17.40	-1.31	1.44	-4.29	1.66	0.3699	-0.11	1.42	-3.05	2.84	0.9418
	Week 36-44	16	-3.70	1.56	-6.92	-0.47					0.0264 ^A					0.0264 ^A
	Screening	24	18.71	1.51	15.58	21.83						-1.60	1.98	-5.70	2.50	0.4278
	Day 1	23	20.31	1.73	16.73	23.89	1.60	1.98	-2.50	5.70	0.4278					
Disordered Movement Log	Week 8	21	17.80	1.25	15.22	20.38	-0.91	1.58	-4.17	2.36	0.5723	-2.50	1.72	-6.06	1.05	0.1581
	Week 16	17	19.13	1.77	15.47	22.79	0.42	2.21	-4.14	4.99	0.8502	-1.18	1.68	-4.66	2.30	0.4910
	Week 36	16	18.54	1.64	15.14	21.95	-0.17	2.04	-4.40	4.06	0.9361	-1.77	1.81	-5.51	1.98	0.3396
	Week 44	16	21.11	1.53	17.94	24.27	2.40	1.90	-1.53	6.33	0.2196	0.80	1.30	-1.89	3.48	0.5448
	Week 36-44	16	-2.56	1.45	-5.57	0.44					0.0909 ^A					0.0909 ^A
	Screening	24	1.12	0.23	0.65	1.59						-0.13	0.15	-0.43	0.17	0.3798
ICR	Day 1	23	1.25	0.24	0.76	1.73	0.13	0.15	-0.17	0.43	0.3798					
	Week 8	21	1.06	0.24	0.56	1.55	-0.06	0.15	-0.36	0.24	0.6798	-0.19	0.11	-0.43	0.04	0.1039
	Week 16	17	1.12	0.24	0.61	1.62	0.00	0.16	-0.33	0.33	0.9931	-0.13	0.15	-0.44	0.18	0.3970
	Week 36	16	0.97	0.26	0.42	1.51	-0.15	0.21	-0.57	0.28	0.4767	-0.28	0.17	-0.62	0.07	0.1071
	Week 44	16	0.97	0.26	0.44	1.50	-0.15	0.20	-0.55	0.26	0.4590	-0.28	0.14	-0.57	0.02	0.0644
	Week 36-44	16	0.00	0.07	-0.15	0.15					0.9822 ^A					0.9822 ^A
ICR	Screening	24	12.13	0.57	10.95	13.30						0.13	0.58	-1.08	1.33	0.8265
	Day 1	23	12.00	0.72	10.51	13.48	-0.13	0.58	-1.33	1.08	0.8285					
	Week 8	21	10.01	0.71	8.55	11.47	-2.12	0.68	-3.52	-0.71	0.0049	-1.99	0.67	-3.37	-0.61	0.0068
	Week 16	17	9.16	0.86	7.38	10.93	-2.97	0.98	-4.99	-0.95	0.0059	-2.84	1.01	-4.92	-0.76	0.0055
	Week 36	16	9.35	0.97	7.34	11.36	-2.78	0.99	-4.83	-0.72	0.0104	-2.65	0.79	-4.29	-1.00	0.0097
	Week 44	16	11.20	0.88	9.38	13.01	-0.93	1.02	-3.05	1.19	0.3732	-0.80	0.95	-2.77	1.17	0.0029
ICR	Week 36-44	16	-1.85	1.31	-4.55	0.86					0.1713 ^A					0.1713 ^A

^ALSM p-value for change from Week 36 to 44. LSM, Standard Error (SE), and P-value are based on the mixed model for the repeated measures using time as a fixed within subject factor.

All statistical tests were two-sided. No adjustment was made for the multiple comparison.

Extended Data Table 5 | Descriptive statistics of change in six outcomes included in the MDRI (SBRS, CSHQ, NCCPC-R, PROMIS Fatigue, APSI and 7-d disordered movement log) and ICR during and after treatment with anakinra

Outcome	Time	N	Median	Q ₁ ^	Q ₃ ^	Minimum	Maximum	Range	P-value [†]
CSHQ	Day1 to Week 8	21	1.0	-2.0	5.0	-7.0	12.0	19.0	0.1653
	Day1 to Week 16	17	1.0	-1.0	4.0	-16	10.0	26.0	0.2953
	Day1 to Week 36	16	1.5	-5.0	4.5	-16	11.0	27.0	0.8900
	Week 36 to Week 44	16	-3.5	-5.0	0.5	-8	12.0	20.0	0.2817
	Day 1 to Week 44	16	-1.5	-5.5	2.0	-12	8.0	20.0	0.2467
SBRS total	Day1 to Week 8	21	0.1	-0.1	0.7	-0.5	1.9	2.4	0.1873
	Day1 to Week 16	17	0.4	0.1	0.6	-0.6	1.6	2.2	0.0038
	Day1 to Week 36	16	0.6	0.2	0.8	-0.7	2.3	3v	0.0027
	Week 36 to Week 44	16	-0.1	-0.9	0.3	-2.0	0.7	2.7	0.1167
	Day 1 to Week 44	16	0.1	-0.2	0.6	-1.6	2.4	4.0	0.2078
NCCPC-R	Day1 to Week 8	21	2.0	-2.0	11.0	-21.0	29.0	50.0	0.1158
	Day1 to Week 16	17	1.0	-1.0	9.0	-9	21.0	30.0	0.1732
	Day1 to Week 36	16	0.0	-2.0	11.0	-10	30.0	40.0	0.2209
	Week 36 to Week 44	16	-1.0	-10.5	2.5	-24	11.0	35.0	0.3203
	Day 1 to Week 44	16	2.0	0.0	8.0	-28	13.0	41.0	0.2097
APSI - short	Day1 to Week 8	21	-1.0	-2.0	5.0	-12	11.0	23.0	0.4981
	Day1 to Week 16	17	2.0	0.0	6.0	-5.0	9.0	14.0	0.0439
	Day1 to Week 36	16	1.5	0.0	5.0	-6.0	15.0	21.0	0.0883
	Week 36 to Week 44	16	-0.5	-5.5	0.5	-18.0	5.0	23.0	0.1519
	Day 1 to Week 44	16	0.0	-1.5	3.0	-18	6.0	24.0	0.7766
Fatigue - short	Day1 to Week 8	21	1.0	0.0	8.0	-8.0	24.0	32.0	0.1622
	Day1 to Week 16	17	1.0	-1.0	6.0	-14.0	14.0	28.0	0.2936
	Day1 to Week 36	16	1.5	-4.0	7.5	-9.0	16.0	25.0	0.3834
	Week 36 to Week 44	16	-3.5	-5.5	3.0	-16.0	8.0	24.0	0.0803
	Day 1 to Week 44	16	-0.5	-3.5	1.0	-14.0	10.0	24.0	0.4553
Disordered Movement Log	Day1 to Week 8	21	0.0	0.0	0.3	-0.2	2.3	2.5	0.0560
	Day1 to Week 16	17	0.0	-0.1	0.1	-0.8	2.3	3.1	0.7007
	Day1 to Week 36	16	0.0	-0.1	0.4	-0.4	2.3	2.7	0.2744
	Week 36 to Week 44	16	0.0	0.0	0.0	-0.9	0.6	1.4	0.9375
	Day 1 to Week 44	16	0.1	0.0	0.3	-0.4	2.3	2.7	0.0498
ICR	Day1 to Week 8	21	2.0	-1.0	4.0	-2.0	9.0	11.0	0.0099
	Day1 to Week 16	17	3.0	0.0	5.0	-5.0	11.0	16.0	0.0288
	Day1 to Week 36	16	2.5	0.0	4.0	-2.0	9.0	11.0	0.0068
	Week 36 to Week 44	16	-1.0	-4.5	1.0	-16.0	4.0	20.0	0.2572
	Day 1 to Week 44	16	2.0	-1.5	3.0	-8.0	4.0	12.0	0.4497

[^]Q₁ = 25th Percentile; Q₃ = 75th Percentile
 Range = Maximum - Minimum
[†] Based on the Signed Rank Test. No adjustment made for the multiple testing.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☐	☒ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give <i>P</i> values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Flow cytometry data were acquired using BD FACS Aria III using BD FACSDiva v9.0.1.
Data analysis	SAS v9.4 (SAS Institute, Cary, NC); FlowJo v10.8.1;

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The de-identified individual participant data that underlie the results reported in this article (including text, tables, and figures) are included in Supplementary Data File 1.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Participant sex was collected from the parent/caregiver. Gender data was not collected. This is due to the severe cognitive deficits in our study population such that they are unable to self report sex or gender. Sex and/or gender were not considered in the study design.
Reporting on race, ethnicity, or other socially relevant groupings	Participant race and ethnicity was collected from the parent/caregiver using the NIH reporting categories. Participants were unable to self-report due to cognitive deficits. Race and ethnicity was not included in our statistical analysis due to our sample size. Race and ethnicity are reported in Table 1.
Population characteristics	These are listed in Table 1. They are age, race, ethnicity, sex, type of MPS III, past experimental therapy with gene therapy or enzyme replacement therapy, and adaptive behavior level using the Vineland III.
Recruitment	Participants were recruited through clinicaltrials.gov, the Cure Sanfilippo Foundation website, Social Media, and word of mouth. This may bias against individuals who do not access the Internet.
Ethics oversight	The John F. Wolf, M.D. Human Subjects Committee at the Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	In designing our study, we initially chose a sample size of 20 participants based on considerations of feasibility, including resource constraints and the availability of participants with this rare disease. Our primary focus was on ensuring that the study could be completed within our budget and reasonable time-frame, while still maintaining the integrity of our research question. Now that the study is completed, we are pleased to report both clinically and statistically significant results despite the relatively small sample size.
Data exclusions	No data were excluded.
Replication	All surveys were completed at both screening and 8 weeks later prior to the first dose of study drug (anakinra). There were no statistically significant differences between these two timepoints.
Randomization	This was a Phase 1/2 open-label study so no randomization was done. Due to the rare nature of the disease and thus small sample size, no potential covariates were controlled for.
Blinding	N/A - open-label study

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

Identification of blood cell subtypes was performed as follows: briefly, monocytes were gated within the myeloid cell population identified by excluding B cells (CD19-APC-Cy7 positive cells BD cat#561743) and T cells (CD3-PE positive cells Fisher Scientific Cat #555333) from the whole blood population. Within the myeloid population, natural killer cells (NK cells) were excluded using CD56 positive cells (CD56-FITC+ and CD14-Alexa-647- cells cat#340410 and 562690 respectively). Subsequently, neutrophils were identified as bright CD16-PerCP-Cy5.5+ (BD cat# 560717) high side scatter cells (SSC). Cells that were not bright CD16 (neutrophils) in the FSC plot were identified as monocyte. These cells expressed CD14 and CD16. CD4-APC-Cy7+ cells (BD cat # 566319) and CD8-PE-Cy7+ cells (BD cat# 335787) were gated within the CD3+ cells of the whole blood, excluding B cells (CD19-APC+ cells BD cat# 555415), and B cells were gated as CD19+ cells.

List of antibodies

Antibody Clone Fluorophore Cat.no.

CD3 UCHT1 PE 555333

CD4 SK3 APC-Cy7 341095

CD8 SK1 PE-Cy7 335787

CD14 MOP9 Alexa-Fluor 647 562690

CD16 3G8 PerCP-Cy 5.5 560717

CD19 SJ25C1 APC-Cy7 557791

CD19 HIB19 APC 555415

CD56 NCAM16.2 FITC 340410

The antibodies were diluted at a ratio of 1.5:200 and then titrated against blood samples to assess reactivity and binding efficiency.

Validation

All antibodies were commercially available and were applied according to the manufacturers' instructions. Validation was performed per DIN EN ISO 15189 criteria.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

NCT04018755

Study protocol

Included with submission

Data collection

Data was collected from January 2020 through March 2023 at a single site, The Lundquist Institute at Harbor-UCLA Medical Center and via telemedicine visits conducted by the PI and sub-I.

Outcomes

All primary and secondary study endpoints were defined according to the aim of the study and prespecified in the clinical protocol.

Primary endpoints were:

Phase 1: Incidence of treatment-emergent adverse events and laboratory values over 8 weeks of treatment to known frequency of anakinra-related AEs in other populations.

Phase 2: Need for dose escalation as determined by within individual change over 8-week treatment period compared to change over 8-week observational period in the 2 most bothersome symptoms for each enrolled patient, selected from measures for the MDRI.

Secondary endpoints included

- A MDRI comprised of:

1. Sanfilippo Behavior Rating Scale (SBRS)
2. Child Sleep Health Questionnaire (CSHQ)
3. Autism Parenting Stress Index (APSI)
4. PROMIS Fatigue - Parent Proxy Custom Short Form
5. Movement disorder (e.g. dystonia, chorea, etc.): Parent reported duration and severity.
6. Non-communicating Children's Pain Checklist-Revised (NCCPC-R)

- Individual Clinical Response (ICR) – 5 most impactful clinical problems reported by the caregiver. Sum using 5-point Likert scale for

each ICR element.

Post hoc analysis was done for immunophenotype and correlation of this with change in the secondary outcomes included in the MDRI.

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Fresh whole blood sample collected in CPT tube was washed twice in PBS and then processed for antibody staining (please see Antibody section). When staining procedure was finished, we acquired 50,000 events on the live cells.

Instrument

BD FACS Aria III

Software

Sample acquisition and recording was performed using FACS DIVA software v9.0.1. Post recording analysis was performed by using FlowJO software version 10.8.1

Cell population abundance

Figure 4 shows an example of the cell population abundance and gating strategy for how the data were analyzed.

Gating strategy

Fragments and debris were excluded in FSC vs SSC scatter plot. Doublets of cells were eliminated by plotting SSC-A vs SSC-H. Live cells were identified using the fixable cell viability dye (BD Cat# BDB564996). Identification of blood cell subtypes was performed as follows: briefly, monocytes were gated within the myeloid cell population identified by excluding B cells (CD19-APC-Cy7 positive cells BD cat#561743) and T cells (CD3-PE positive cells Fisher Scientific Cat #555333) from the whole blood population. Within the myeloid population, natural killer cells (NK cells) were excluded using CD56 positive cells (CD56-FITC+ and CD14- Alexa-647- cells cat#340410 and 562690 respectively). Subsequently, neutrophils were identified as bright CD16-PerCP-Cy5.5+ (BD cat# 560717) high side scatter cells (SSC). Cells that were not bright CD16 (neutrophils) in the FSC plot were identified as monocyte. These cells expressed CD14 and CD16. CD4-APC-Cy7+ cells (BD cat # 566319) and CD8-PE-Cy7+ cells (BD cat# 335787) were gated within the CD3+ cells of the whole blood, excluding B cells (CD19-APC+ cells BD cat# 555415), and B cells were gated as CD19+ cells.

- ☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.